FDA Approves Tibsovo for Acute Myeloid Leukemia

MONDAY, July 23, 2018 -- Tibsovo (ivosidenib) tablets have been approved by the U.S. Food and Drug Administration to treat relapsed or refractory acute myeloid leukemia (AML) among people with a defective IDH1 gene. Tibsovo ' s effectiveness was...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news